EMDR treatment for fear of cancer recurrence in familial melanoma patients
EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control Trial
This study is testing if EMDR therapy can help patients with familial melanoma feel less afraid of their cancer coming back.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Leiden University Medical Center Academic / other |
| Locations | 2 sites (Leiden, South Holland and 1 other locations) |
| Trial ID | NCT06767332 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of Eye Movement Desensitization and Reprocessing (EMDR) in reducing fear of cancer recurrence (FCR) among patients with familial melanoma. The study involves a randomized waiting-list control design, where eligible participants will receive up to four 90-minute EMDR sessions. The primary outcome will be measured using the Cancer Worry Scale (CWS), while quality of life will be assessed with the EORTC questionnaire. The trial aims to provide psychological support to patients who experience high levels of FCR, which can significantly impact their quality of life.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years or older who have been diagnosed with familial melanoma and exhibit high levels of fear of cancer recurrence.
Not a fit: Patients who do not have familial melanoma or those with acute psychiatric conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly reduce fear of cancer recurrence and improve the quality of life for patients with familial melanoma.
How similar studies have performed: Previous studies have shown promising results for EMDR in treating various anxiety-related conditions, suggesting potential success for this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * a score of 16 or higher on the FCRI-NL-SF * 18 years or older * diagnosed with familial melanoma Exclusion Criteria: * insufficient knowledge of the Dutch language. * acute psychiatric disease (psychosis, suicidal ideation) * variable dosis of anxiolytics
Where this trial is running
Leiden, South Holland and 1 other locations
- Leiden University Medical Center — Leiden, South Holland, Netherlands (Recruiting)
- Leiden University Medical Centre — Leiden, South Holland, Netherlands (Recruiting)
Study contacts
- Principal investigator: Chris Hinnen, Dr. — Leiden University Medical Centre
- Study coordinator: Sanne K. de Bie, Drs.
- Email: s.k.de_bie@lumc.nl
- Phone: 0031 71 526 3615
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.